Quarterly ResultJul 24, 2026, 03:51 PM
Park Ha Net Loss Narrows 95% to $918K in H1 2026
AI Summary
Park Ha Biological Technology reported a significant reduction in net loss for the six months ended April 30, 2026, narrowing by 95% to $918,282. This improvement was largely due to the absence of a large share-based payment expense recognized in the prior year. Total revenue saw a modest 1% increase, driven by strong product sales growth to non-franchisees, which offset a 35% decline in franchise fees revenue due to a decrease in the number of franchisees. The company also experienced increased selling, marketing, and R&D expenses, and a shift to negative operating cash flow.
Key Highlights
- Net loss significantly narrowed by 95% to $918,282 for the six months ended April 30, 2026.
- Total revenue increased by 1% to $1,257,689 for the six months ended April 30, 2026.
- Product sales revenue grew by 77% to $716,105, driven by non-franchisee sales.
- Franchise fees revenue decreased by 35% to $541,584 due to a reduction in franchisees from 39 to 21.
- Selling and marketing expenses increased by 144% to $560,577.
- General and administrative expenses decreased by 94% to $1,189,274, primarily due to no share-based payment expense in 2026.
- Research and development expenses surged by 431% to $138,618.
- Net cash used in operating activities was $113,727, compared to $245,433 provided in the prior year.
Price Impact
More from BYAH